All articles by GlobalData Healthcare

GlobalData Healthcare

Pfizer’s etrasimod aims to differentiate UC market with strong safety profile

The UC market is forecasted to reach 2031 sales of approximately $9.6bn across the 8MM.

AbbVie and Genmab’s bispecific Epkinly has a first-to-market advantage in DLBCL

GlobalData’s consensus forecast forecasts that Epkinly will achieve blockbuster status by 2027.

Johnson & Johnson’s Tremfya outshines IL-17 inhibitors as plaque psoriasis treatment

The trial exhibited superior and durable clinical efficacy and safety of Tremfya.

Role of machine learning tools in early diagnosis of Parkinson’s disease

GlobalData epidemiologists forecast that there are currently over 2.4 million diagnosed prevalent cases of PD in 7MM.

The troubling health impacts of air pollution

Key pollutants of interest included black carbon, small particulate matter (PM₂.₅), nitrogen dioxide (NO₂), and sulphur dioxide (SO₂).

Top three unmet needs to target in Parkinson’s disease

In the early stages of Parkinson’s disease, motor symptoms are well managed by levodopa.

Childhood adversity potentially pre-disposes young adults to type 2 diabetes

GlobalData estimate that by the end of 2023, there will be 234 million diagnosed prevalent cases of type 2 diabetes in men and women in the 16 major pharmaceutical markets.

Rate of breast density loss may indicate risk of breast cancer

In 2023, GlobalData epidemiologists predict over 278,000 diagnosed incident cases of invasive breast cancer.

National Lipid Day: a timely reminder of dyslipidemia

Several risk factors can contribute to the development of dyslipidemia, including consuming a diet high in saturated fats.